About this trial
Wound management is a real public health issue in France. To date, a wide range of devices exists to treat these wounds, depending on their nature and stage of evolution. Honey has been proposed for the care of wounds and is effective in reducing the surface of wounds and the pain perceived by patients. Inanition, its use is very simple compared to usual care, requiring different types of dressing accross time. In the intensive care unit, patients are prone to suffering or developing numerous types of wound, but the interest of honey has not been investigated yet.
We propose a prospective, monocentric, randomized, single-blind, controlled clinical trial to assess the efficacy of managing acute cutaneous wounds with honey (Activon®) compared with standard care, in intensive care patients. The primary endpoint is the percentage of wound surface area reduction measured at 15 days from inclusion.
Eligibility criteria
Qualifiers
Hospitalization in surgical intensive care unit A -USC PTO CHU ANGERS
Informed consent signed by patient or relative (or emergency inclusion procedure)
Patient with one or more wounds ≥ 4 cm2, evolving for less than 8 days, including: stage 2, 3, 4 pressure sores, lacerations, ulcers, dermabrasions and scar disunions.
Disqualifiers
Patients with honey intolerance/allergy to bee stings
Patients with wounds lasting more than 8 days
Patient with a bleeding wound,
Patient with a tunneled wound
Trial design
Treatments tested in this trial
- medical honey Activon® 25g Tube
- standard of care
Treatment groups
Locations
1Sponsors and collaborators
University Hospital, Angers
Lead sponsor